Incyte Corporation (NASDAQ:INCY) is back in the biotech deal spotlight. The company is reportedly nearing an agreement to acquire privately held Star Therapeutics for up to $2 billion, including about $1.25 billion in upfront cash and $750 million in milestones. The target brings VGA039, a late-stage, once-monthly injectable therapy for von Willebrand disease. That is the most common inherited bleeding disorder. The timing matters. Incyte just reported a strong Q1 2026, with total revenue up 21% year-over-year to $1.27 billion and net sales up 20% to $1.1 billion. Jakafi still remains the main revenue anchor, but management is clearly preparing for life beyond its expected 2028 patent expiration. The Star deal would be the first major acquisition under CEO Bill Meury. It also fits his stated focus on portfolio growth, late-stage assets, and disciplined business development.
A Stronger Hematology Portfolio Beyond Jakafi
The simplest read is this: Incyte needs more hematology depth before Jakafi loses exclusivity. Jakafi still delivered $758 million in Q1 2026 sales. That was up 7% year-over-year. It remains the company’s most important product by far. Still, the 2028 patent cliff is not a small issue.
Star Therapeutics could help soften that transition. VGA039 would not replace Jakafi directly. It treats a different condition. But it would expand Incyte’s blood-disorder footprint into von Willebrand disease. That gives the company another specialty hematology asset with late-stage potential.
This matters because Incyte is already building a wider hematology engine. Niktimvo, Monjuvi, and the mutant CALR antibody ’989 are all part of that shift. VGA039 could add another layer to that strategy. It would also reduce reliance on a single cornerstone product. That does not remove execution risk. But it gives management another route to long-term portfolio balance.
A More Convenient Option For Von Willebrand Disease
VGA039’s main appeal is its dosing profile. Current von Willebrand disease treatments often involve frequent infusions. That can be a burden for patients. It can also make preventive treatment harder to maintain over time.
Star’s drug is designed as a once-monthly injection. If approved, it could become a more convenient option for preventing bleeding episodes. That matters in a disease where regular care can be uneven. About 35,000 patients have been treated at U.S. hemophilia centers in recent years. Analysts believe the real patient pool could be much larger.
For Incyte, this creates a market expansion angle. The company would not just be buying a drug. It would be buying a possible way to reach undertreated patients. That said, this will not be an automatic commercial win. Bleeding disorders require careful education, specialist engagement, and strong payer evidence. Still, the convenience angle gives Incyte a clear starting point for differentiation.
Commercial Infrastructure That Could Support Another Launch
Incyte has been preparing for a busy launch cycle. Management has talked about building a more integrated U.S. commercial organization. The goal is better analytics, market access, sales operations, and patient services. That structure is already being lined up for Jakafi XR, povorcitinib, Monjuvi, and Opzelura.
VGA039 could benefit from that setup. A once-monthly injectable for a rare bleeding disorder would need strong patient support. It would also need reimbursement navigation and education at hemophilia treatment centers. Incyte already works in specialist-driven markets. That gives it some relevant muscle.
Still, von Willebrand disease is not the same as oncology or dermatology. Incyte would need focused hematology expertise in bleeding disorders. The company may also need to build new relationships in hemophilia centers. So the synergy is real, but not plug-and-play. The benefit depends on how smoothly Incyte adapts its existing launch machine to a new niche.
A Late-Stage Asset That Diversifies Pipeline Risk
Incyte’s pipeline is broad, but it is also expensive. The company is advancing ’989 in CALR-mutated blood cancers. It is also moving ’734 in KRAS G12D pancreatic cancer, ’667 in ovarian cancer, and povorcitinib in dermatology. That gives Incyte many shots on goal. It also creates plenty of development risk.
Star Therapeutics adds a different kind of asset. VGA039 is late-stage and sits outside Incyte’s core oncology pipeline. That could help diversify clinical and commercial risk. The deal structure may also help. A portion of the $2 billion value is tied to milestones, not just upfront cash.
That said, the upfront payment is still large. Incyte would be spending $1.25 billion before knowing the full commercial outcome. That makes trial success, regulatory review, and launch execution very important. The acquisition could improve portfolio balance. But it could also increase pressure on capital allocation if other pipeline programs demand more investment.
Final Thoughts
The Star Therapeutics deal could give Incyte a useful hematology-adjacent asset at a sensitive time. VGA039 may expand the company’s reach into von Willebrand disease. It may also add a more convenient treatment profile in a market with unmet needs.
But this acquisition could cut both ways. The price is meaningful. The market will require education. Incyte already has a packed launch and pipeline calendar. That creates execution risk.
Valuation also deserves a grounded view. As of June 5, 2026, Incyte traded at 3.07x LTM EV/revenue, 3.82x LTM price/sales, 10.64x LTM EV/EBITDA, 11.33x LTM EV/EBIT, and 14.50x LTM diluted P/E. Those multiples are not stretched like a speculative biotech name. They also are not distressed. The market seems to be pricing Incyte as a profitable company with pipeline optionality and clear patent-cliff risk.
So, the deal could make strategic sense. It could also add another layer of complexity. For now, the Star Therapeutics interest shows how Incyte is trying to manage the next chapter without relying only on Jakafi.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
